Sanofi (SNYNF) Change in Accured Expenses (2009 - 2015)
Sanofi's (SNYNF) quarterly Change in Accured Expenses came in at $13.5 billion in Q2 2015, up 4.4% year-on-year from $12.9 billion in Q2 2014, and down 5.13% quarter-over-quarter from $14.2 billion in Q4 2014.
Sanofi (SNYNF) Change in Accured Expenses (2009 - 2015) Analysis & Trends
Sanofi has disclosed Change in Accured Expenses across 6 years of filings, most recently posting $13.5 billion for Q2 2015.
- Change in Accured Expenses for Q2 2015 came in at $13.5 billion, up 4.4% year-over-year; the trailing twelve-month figure through Jun 2015 was $13.5 billion (up 4.4% YoY), and the FY2014 annual result was $15.1 billion, up 16.91% from the prior year.
- Change in Accured Expenses came in at $13.5 billion for Q2 2015 at Sanofi, down from $14.2 billion in the prior quarter.
- In the past five years, Change in Accured Expenses ranged from a high of $14.2 billion in Q4 2014 to a low of $12.9 billion in Q4 2012.
- The 4-year median for Change in Accured Expenses is $13.2 billion (2013), against an average of $13.3 billion.
- Across the five-year window, Change in Accured Expenses climbed 2.63% in 2013 and increased 7.26% in 2014, its largest moves.
- Sanofi's Change in Accured Expenses stood at $12.9 billion in 2012, then rose by 2.63% to $13.2 billion in 2013, then gained by 7.26% to $14.2 billion in 2014, then fell by 5.13% to $13.5 billion in 2015.
- The last three Change in Accured Expenses figures came in at $13.5 billion (Q2 2015), $14.2 billion (Q4 2014), and $12.9 billion (Q2 2014), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 96,436,181.12 Bn | 96,436,176.16 Bn | 7.76 Bn | - |
| 2 | Eli Lilly | 1,017.30 Bn | 1,012.01 Bn | 16.22 Bn | - |
| 3 | Johnson & Johnson | 579.61 Bn | 557.55 Bn | 15.96 Bn | -629.00 Mn |
| 4 | AbbVie | 402.30 Bn | 392.96 Bn | 10.78 Bn | -1.59 Bn |
| 5 | Merck | 294.24 Bn | 288.59 Bn | 12.09 Bn | - |
| 6 | Amgen | 191.82 Bn | 179.78 Bn | 5.87 Bn | -75.00 Mn |
| 7 | Gilead Sciences | 155.93 Bn | 148.21 Bn | 5.52 Bn | -702.00 Mn |
| 8 | Pfizer | 149.05 Bn | 136.28 Bn | -1.21 Bn | - |
| 9 | Bristol Myers Squibb | 116.33 Bn | 105.88 Bn | 8.07 Bn | -3.50 Bn |
| 10 | Sanofi | - | - | 9.49 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2015 | 13.47 Bn |
| Jun 30, 2015 | 13.47 Bn |
| Dec 31, 2014 | 14.20 Bn |
| Dec 31, 2014 | 14.20 Bn |
| Jun 30, 2014 | 12.91 Bn |
| Jun 30, 2014 | 12.91 Bn |
| Dec 31, 2013 | 13.24 Bn |
| Dec 31, 2013 | 13.24 Bn |
| Dec 31, 2012 | 12.90 Bn |
| Dec 31, 2012 | 12.90 Bn |
| Jun 30, 2010 | 10.09 Bn |
| Jun 30, 2010 | 10.09 Bn |
| Dec 31, 2009 | 11.96 Bn |
| Dec 31, 2009 | 11.96 Bn |